Pimicotinib exhibits anti-tumor activity in NCI-H2122 PBMC humanized mice and LLC syngeneic mice, with better efficacy when used in combination with Sotorasib. It can lead to a decrease in the number of immune suppressive tumor associated macrophages, enhanced regulation of the tumor microenvironment related to anti-tumor immunity, and increased infiltration of CD8 T cells.